Browsing Tag
psychedelic biotech
4 posts
Why next-generation MDMA therapeutics are becoming the new battleground in psychedelic biotech
Why next-generation MDMA therapeutics are reshaping psychedelic biotech strategy, investor expectations, and commercialization competition.
What Restora Neurosciences reveals about the next financing model for psychedelic-adjacent CNS biotech
What does Restora Neurosciences reveal about the future of CNS biotech financing? Read the full Business News Today analysis.
After AbbVie took bretisilocin, what’s next for Gilgamesh Pharma’s neuropsychiatric pipeline?
Gilgamesh Pharma, newly spun out from the AbbVie deal, holds a promising psychiatric drug pipeline. Here's what the industry should expect next.
Who’s funding the psychedelic revolution in pharma? Follow the money from PIPEs to Big Pharma M&A
Psychedelic biotech is evolving—from VC hype to pharma buyouts. Discover who’s funding the next generation of depression treatments in 2025.